Dean Rudge

Birmingham

Deputy Editor at Generics Bulletin

Assistant editor at Generics bulletin

Articles

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

1 week ago | insights.citeline.com | Dean Rudge

Tevogen Will House Generics Unit In Much-Expanded New HeadquartersMove Will Double Footprint, Consolidate Its R&D And Cross-Functional TeamsTevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.
Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

1 week ago | insights.citeline.com | Dean Rudge

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s NextExclusive Interview Includes Discussion Of Vision To Grow In US BiosimilarsIn an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.
Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

1 week ago | insights.citeline.com | Dean Rudge

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-UpPartnership Centers On TEV-56278, A Next-Generation Anti-PD1–IL2 Fusion ProteinTeva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w
Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement

1 week ago | insights.citeline.com | Dean Rudge

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch AgreementLupin became the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster. Lupin will be allowed to launch its generic Wakix in January 2030 or July 2023 if pediatric exclusivity is included. (Shutterstock)
‘I Saw An Unpolished Diamond’: Iconovo CEO Wäborg On Breaking Even In 2027 And Beyond

1 week ago | insights.citeline.com | Dean Rudge

‘I Saw An Unpolished Diamond’: Iconovo CEO Wäborg On Breaking Even In 2027 And BeyondSwedish Firm Is Developing Generic Dual-Acting Inhalers And Working Towards ReformulationsIn an exclusive interview, Iconovo CEO Johan Wäborg outlines the company’s strategy to become a leader in dry powder inhalation by focusing on platform development, reformulated therapies, and B2B licensing, with a plan to break even by 2027.
Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

2 weeks ago | insights.citeline.com | Dean Rudge

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar ManufacturingTech Transfer Aims To Accelerate Regulatory Approvals, OneSource Also Invests In FirmXbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.
Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

2 weeks ago | insights.citeline.com | Dean Rudge

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative SetbacksAmgen’s Pavblu ‘Clearly Leaning Into Physician Economics’ According To RegeneronRegeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.
Lupin Concedes To Wakix IP With 2030 Launch Date Agreement

2 weeks ago | insights.citeline.com | Dean Rudge

Lupin Concedes To Wakix IP With 2030 Launch Date AgreementIndian Firm Is Third ANDA Sponsor To Settle Patent-Infringement LitigationAhead of a bench trial beginning in February 2026, Lupin has become the latest ANDA sponsor to settle patent-infringement litigation over Harmony Biosciences’ Wakix (pitolisant hydrochloride), which has been touted as a potential blockbuster by the end of the decade.
Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro Partnership

2 weeks ago | insights.citeline.com | Dean Rudge

Big In Japan: Samsung Bioepis Looks To Increase Presence With Nipro PartnershipLicense, Development And Commercialization Agreement Includes Ustekinumab BiosimilarAhead of being spun out of its parent company Samsung Biologics later this year, Samsung Bioepis has struck an agreement to bolster its presence in another Asian market and one of the largest global pharma markets.
AstraZeneca Agrees Last-Minute $50m Settlement In Seroquel XR Delay Case

2 weeks ago | insights.citeline.com | Dean Rudge

AstraZeneca Agrees Last-Minute $50m Settlement In Seroquel XR Delay CaseANDA Filer Handa Also Pens Much Smaller Settlement; Follows Six Years Of LitigationA class action suit alleging AstraZeneca delayed generic competition for Seroquel XR by making illegal agreements that stifled market entry for generic quetiapine competitors has been dismissed after the originator agreed to settle for tens of millions of dollars.